Foods That Actually Lower LDL: What the Best Trials Show

If lowering LDL cholesterol is your goal, the best-supported foods are more useful than glamorous: plant sterols or stanols, soluble fiber from oats, barley, or psyllium, and unsaturated fats used in place of saturated fats. A 2021 evidence review found that these were the only food categories with high-certainty evidence for LDL reductions of at least 0.20 mmol/L—about 7.7 mg/dL.

The same review delivered an awkward finding for espresso devotees: unfiltered coffee has high-certainty evidence for raising LDL. Meanwhile, dark chocolate, garlic supplements, apple cider vinegar, and coconut oil do not have high-quality evidence for a clinically meaningful LDL reduction. The useful LDL protocol is not exotic. It is mostly a series of substitutions repeated long enough to matter.

The short list with high-grade evidence

Schoeneck et al.'s 2021 systematic review assessed 108 systematic reviews plus 20 additional randomized controlled trials using GRADE, a framework that rates confidence in evidence. Included studies lasted at least 13 days. The review identified three categories that met both tests that matter here: high-certainty evidence and an LDL reduction of at least 0.20 mmol/L.

• Plant sterols and stanols. These compounds reduce intestinal cholesterol absorption. Fortified foods and supplements are common delivery methods. A practical target is about 2 g daily, although the review abstract does not provide a food-specific pooled estimate or a dose-response analysis.
• Unsaturated-fat-rich foods replacing saturated and trans fats. Rapeseed, better known in the United States as canola oil, was the prototype. The intervention is the swap: use oils rich in mono- and polyunsaturated fats instead of butter, coconut oil, or other saturated-fat-heavy fats.
• Viscous soluble fiber. Oats, barley, and psyllium made the high-evidence list. Common targets are roughly 3 g daily of oat beta-glucan or 10–12 g daily of psyllium, but the available review summary cannot establish a minimum effective dose for every product.

Across these categories, the review placed typical effects in the 0.20–0.40 mmol/L range. It did not report distinct pooled estimates for sterols, canola oil, oats, barley, and psyllium in its abstract, so pretending that one food wins by 0.03 mmol/L would be decorative precision.

The National Lipid Association's 2023 clinical perspective reaches the same practical conclusion. For adults with dyslipidemia, it recommends reducing cholesterol-raising saturated and trans fats while increasing unsaturated fats, plant proteins, viscous fiber, and plant sterols or stanols. It also classifies coconut oil as a cholesterol-raising fat. This is a clinical perspective rather than a GRADE-rated food-by-food review, but its recommendations map closely onto the stronger randomized evidence.

Coffee can quietly work against the plan

Unfiltered coffee had high-certainty evidence for a moderate-to-large LDL increase in the Schoeneck review. French press, espresso, and Turkish coffee leave through diterpenes called cafestol and kahweol, which paper filters remove. These compounds increase hepatic LDL-cholesterol synthesis. Paper-filtered drip coffee did not share the effect in the review.

This does not make coffee a forbidden substance or turn every latte into a cardiovascular crime scene. It does mean that someone who drinks unfiltered coffee daily and is trying to lower LDL has a simple, evidence-based experiment available: switch to paper-filtered coffee and retest lipids after enough time for the result to be meaningful.

Popular does not mean clinically useful

Dark chocolate, garlic supplements, apple cider vinegar, and coconut oil did not reach the high-evidence, clinically meaningful LDL threshold in the 2021 review. Coconut oil deserves special caution because its saturated fat content fits the NLA's cholesterol-raising-fat category. A food can contain polyphenols, taste expensive, and still fail to move LDL enough to guide treatment.

Green tea had moderate-certainty evidence for small-to-moderate LDL reductions, but its effect fell below the review's high-confidence clinical-significance threshold. Turmeric or curcumin is more complicated: moderate-certainty evidence suggested moderate-to-large reductions in selected populations, especially people with polycystic ovary syndrome or metabolic syndrome. That does not establish the same effect in healthy adults or in people with isolated high LDL.

A 2025 meta-analysis of dietary polyphenols in people with PCOS found heterogeneous metabolic effects across interventions and populations. Jian et al. therefore supports caution about exporting a result from a metabolically specific group to everyone buying turmeric or dark chocolate for their lipid panel.

Whole dietary patterns help, but they have a ceiling

Food-by-food evidence does not mean people should eat a pile of psyllium beside a plate of butter. Dietary patterns determine whether those swaps happen consistently. A 2025 GRADE-assessed meta-analysis of DASH found improved lipid measures, including LDL, among people with overweight or obesity. A separate 2021 meta-analysis found DASH-related improvements in metabolic risk factors among patients with chronic disease, though effects across real-world populations are not uniform.

Whole-diet trials in postmenopausal women point in the same direction with more uncertainty. Amiri et al. reviewed 21 controlled trials and reported heterogeneous, inconsistent results for lipid and other cardiovascular risk factors. Menopause raises cardiometabolic risk, but the review does not justify a universal LDL effect for every diet pattern in every postmenopausal woman.

Soy is useful mainly as a substitution, not as an LDL miracle. A 2024 systematic review and meta-analysis of randomized trials examined soymilk substituted for cow's milk and found improvements in intermediate cardiometabolic outcomes, including LDL cholesterol. The broader food review classed soy protein's LDL effect as a small reduction with moderate-certainty evidence. Replacing cow's milk with soymilk may help; it does not match the evidence grade or effect threshold of sterols, soluble fiber, and unsaturated-fat substitutions.

LDL is a biomarker, not a guarantee

Lower LDL is an important treatment target, but dietary LDL changes are still surrogate outcomes. A 2021 Cochrane review of vegan dietary patterns found low-certainty evidence for reductions in actual cardiovascular events in primary and secondary prevention, despite favorable lipid effects. The limitation is not that LDL is irrelevant. It is that short dietary trials measuring LDL cannot, by themselves, tell us the precise reduction in heart attacks or strokes that follows.

Many food trials are brief: the Schoeneck review accepted studies as short as 13 days. Effects may plateau, fade, or prove difficult to maintain over years. Food research also has substantial industry involvement, including in nut, sterol, and soy studies, which can increase the risk that small positive findings receive more attention than null results.

What to do with this evidence

Build meals around the three high-evidence moves: add viscous soluble fiber daily, use unsaturated oils in place of saturated fats, and consider plant sterols or stanols. If you drink French press, espresso, or Turkish coffee regularly, paper-filtered coffee is a rational switch when LDL is elevated. Use DASH-style eating as a structure for these changes, especially if weight, blood pressure, or glucose also need attention.

Expect a real but bounded effect. Combining the three high-evidence strategies is estimated to lower LDL by roughly 10–20% from a typical baseline. Moderate- to high-intensity statins usually lower LDL by about 35–55%. Diet is a meaningful adjunct for dyslipidemia; for established hypercholesterolemia or high cardiovascular risk, it is rarely a substitute for indicated medication and clinical care.